ABCR  Vol.4 No.4 , October 2015
Familial versus Sporadic Breast Cancer: Different Treatments for Similar Tumors?
ABSTRACT
Objective: It is unclear if and to what extent family history of breast/ovarian cancer or BRCA1/2-mutation carriership influences breast cancer treatment strategy. We investigated whether treatment differed between patients from BRCA1/2 families and those unselected for family history. Methods: We included 478 BRCA1/2-related patients referred for genetic testing before or after diagnosis. Two references were used: 13,498 population-based and 6896 hospital-based patients. Surgical treatment and adjuvant chemotherapy use was analyzed using logistic regression models, stratified by tumor size, nodal status, age at and period of diagnosis, and estrogen receptor status (ER). Results: BRCA1/2 cases aged 35 - 52 years at diagnosis and/or with tumors < 2 cm were more likely to have undergone a modified radical mastectomy (Odd Ratios (OR) ranging from 2.8 to 5.1) compared to the references. This effect was most pronounced in patients treated after 1995 (OR 5.7 to 10.3). Compared to the reference groups, chemotherapy was more often administered to BRCA1 and ER-negative BRCA1/2-cases irrespective of age and nodal status (OR 1.9 to 24.3). Conclusion: After 1995 treatment of BRCA1/2-associated patients consisted notably of more mastectomies and adjuvant chemotherapy than their population-based counterparts with the same tumor characteristics. There is a need to be aware of such differences in daily practice and interpretation of survival studies on BRCA1/2 mutation carriers.

Cite this paper
Engelhardt, E. , Kriege, M. , Hooning, M. , Seynaeve, C. , Tollenaar, R. , Asperen, C. , Ausems, M. , Poll-Franse, L. , Mook, S. , Verhoef, S. , Rookus, M. , Collaborators, H. , Schmidt, M. (2015) Familial versus Sporadic Breast Cancer: Different Treatments for Similar Tumors?. Advances in Breast Cancer Research, 4, 87-99. doi: 10.4236/abcr.2015.44010.
References
[1]   Antoniou, A., Pharoah, P., Narod, S., Risch, H., Eyfjord, J., Hopper, J., et al. (2003) Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies. The American Journal of Human Genetics, 72, 1117-1130.
http://dx.doi.org/10.1086/375033

[2]   Kiemeney, L., Lemmers, F., Verhoeven, R., Aben, K., Honing, C., de Nooijer, J., et al. (2008) De kans op kanker voor Nederlanders. Nederlands Tijdschrift voor Geneeskunde, 152, 2233-2241.

[3]   Boyle, P. and Levin, B., Eds. (2008) World Cancer Report 2008. International Agency for Research on Cancer (IARC), Geneva, 1-6-2010.

[4]   Soerjomataram, I., Louwman, M., Ribot, J., Roukema, J. and Coebergh, J. (2008) An Overview of Prognostic Factors for Long-Term Survivors of Breast Cancer. Breast Cancer Research and Treatment, 107, 309-330.
http://dx.doi.org/10.1007/s10549-007-9556-1

[5]   Brekelmans, C., Seynaeve, C., Menke-Pluymers, M., Brüggenwirth, H., Tilanus-Linthorst, M., Bartels, C., et al. (2006) Survival and Prognostic Factors in BRCA1-Associated Breast Cancer. Annals of Oncology, 17, 391-400.
http://dx.doi.org/10.1093/annonc/mdj095

[6]   Foulkes, W., Reis-Filho, J. and Narod, S. (2010) Tumor Size and Survival in Breast Cancer—A Reappraisal. Nature Reviews Clinical Oncology, 7, 348-353.
http://dx.doi.org/10.1038/nrclinonc.2010.39

[7]   Tutt, A., Robson, M., Garber, J., Domchek, S., Audeh, M., Weitzel, J., et al. (2010) Oral Poly(ADP-Ribose) Polymerase Inhibitor Olaparib in Patients with BRCA1 or BRCA2 Mutations and Advanced Breast Cancer: A Proof-of-Concept Trial. The Lancet, 376, 235-244.
http://dx.doi.org/10.1016/S0140-6736(10)60892-6

[8]   Bordeleau, L., Panchal, S. and Goodwin, P. (2010) Prognosis of BRCA-Associated Breast Cancer: A Summary of Evidence. Breast Cancer Res Treat, 119, 13-24.
http://dx.doi.org/10.1007/s10549-009-0566-z

[9]   Lee, E., Park, S., Park, B., Kim, S., Lee, M., Ahn, S., et al. (2010) Effect of BRCA1/2 Mutation on Short-Term and Long-Term Breast Cancer Survival: A Systematic Review and Meta-Analysis. Breast Cancer Research and Treatment, 122, 11-25.
http://dx.doi.org/10.1007/s10549-010-0859-2

[10]   Goldhirsch, A., Ingle, J., Gelber, R., Coates, A., Thürlimann, B., Senn, H., et al. (2009) Thresholds for Therapies: Highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009. Annals of Oncology, 20, 1319-1329.
http://dx.doi.org/10.1093/annonc/mdp322

[11]   Maughan, K., Lutterbie, M. and Ham, P. (2010) Treatment of Breast Cancer. American Family Physician, 81, 1339-1346.

[12]   Litiere, S., Werutsky, G., Fentiman, I.S., Rutgers, E., Christiaens, M.R., Van Limbergen, E., et al. (2012) Breast Conserving Therapy versus Mastectomy for Stage I-II Breast Cancer: 20 Year Follow-Up of the EORTC 10801 Phase 3 Randomised Trial. The Lancet Oncology, 13, 412-419.
http://dx.doi.org/10.1016/S1470-2045(12)70042-6

[13]   NABON (2012) Breast Cancer, Dutch Guideline, Version 2.0.
http://www.oncoline.nl/mammacarcinoom

[14]   Early Breast Cancer Trialists’ Collaborative Group (1998) Polychemotherapy for Early Breast Cancer: An Overview of the Randomised Trials. The Lancet, 352, 930-942.
http://dx.doi.org/10.1016/S0140-6736(98)03301-7

[15]   Vervoort, M., Draisma, G., Fracheboud, J., Poll-Franse, L. and de Koning, H. (2004) Trends in the Usage of Adjuvant Systemic Therapy for Breast Cancer in the Netherlands and Its Effect on Mortality. British Journal of Cancer, 91, 242-247.
http://dx.doi.org/10.1038/sj.bjc.6601969

[16]   Vos, E., Linn, S. and Rodenhuis, S. (2006) Effects and Costs of Adjuvant Chemotherapy for Operable Lymph Node Positive Breast Cancer with HER2/Neu Overexpression. Nederlands Tijdschrift voor Geneeskunde, 150, 776-780.

[17]   Early Breast Cancer Trialists’ Collaborative Group (2005) Effects of Chemotherapy and Hormonal Therapy for Early Breast Cancer on Recurrence and 15-Year Survival: An Overview of the Randomised Trials. The Lancet, 365, 1687-1717.
http://dx.doi.org/10.1016/S0140-6736(05)66544-0

[18]   Devilee, P., Tollenaar, R. and Cornelisse, C. (2012) From Gene to Disease; from BRCA1 or BRCA2 to Breast Cancer. Nederlands Tijdschrift voor Geneeskunde, 144, 2549-2551.

[19]   Klitzman, R. and Chung, W. (2010) The Process of Deciding about Prophylactic Surgery for Breast and Ovarian Cancer: Patient Questions, Uncertainties, and Communication. American Journal of Medical Genetics, 152A, 52-66.
http://dx.doi.org/10.1002/ajmg.a.33068

[20]   Meijers-Heijboer, H., Brekelmans, C., Menke-Pluymers, M., Seynaeve, C., Baalbergen, A., Burger, C., et al. (2003) Use of Genetic Testing and Prophylactic Mastectomy and Oophorectomy in Women with Breast or Ovarian Cancer from Families with a BRCA1 or BRCA2 Mutation. Journal of Clinical Oncology, 21, 1675-1681.

[21]   Rebbeck, T., Kauff, N. and Domchek, S. (2009) Meta-Analysis of Risk Reduction Estimates Associated with Risk-Reducing Salpingo-Oophorectomy in BRCA1 or BRCA2 Mutation Carriers. Journal of the National Cancer Institute, 101, 80-87.
http://dx.doi.org/10.1093/jnci/djn442

[22]   Domchek, S., Friebel, T., Neuhausen, S., Wagner, T., Evans, G., Isaacs, C., et al. (2006) Mortality after Bilateral Salpingo-Oophorectomy in BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study. The Lancet Oncology, 7, 223-229.
http://dx.doi.org/10.1016/S1470-2045(06)70585-X

[23]   Rebbeck, T., Friebel, T., Lynch, H., Neuhausen, S., van’t Veer, L., Garber, J., et al. (2004) Bilateral Prophylactic Mastectomy Reduces Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers: The PROSE Study Group. Journal of Clinical Oncology, 22, 1055-1062.

[24]   Graves, K., Peshkin, B., Halbert, C., DeMarco, T., Isaacs, C. and Schwartz, M. (2007) Predictors and Outcomes of Contralateral Prophylactic Mastectomy among Breast Cancer Survivors. Breast Cancer Research and Treatment, 104, 321-329.
http://dx.doi.org/10.1007/s10549-006-9423-5

[25]   Domchek, S., Friebel, T. and Singer, C. (2010) Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers with Cancer Risk and Mortality. Japan Automobile Manufacturers Association, 304, 967-975.
http://dx.doi.org/10.1001/jama.2010.1237

[26]   Klaren, H., van’t Veer, L., van Leeuwen, F. and Rookus, M. (2003) Potential for Bias in Studies on Efficacy of Prophylactic Surgery for BRCA1 and BRCA2 Mutation. Journal of the National Cancer Institute, 95, 941-947.
http://dx.doi.org/10.1093/jnci/95.13.941

[27]   Pijpe, A., Manders, P., Brohet, R., Collée, J., Verhoef, S., Vasen, H., et al. (2010) Physical Activity and the Risk of Breast Cancer in BRCA1/2 Mutation Carriers. Retreats—Breast Cancer Recovery, 120, 235-244.
http://dx.doi.org/10.1007/s10549-009-0476-0

[28]   Sukel, M., van de Poll-Franse, L., Nieuwenhuijzen, G., Vreugdenhil, G., Herings, R., Coebergh, J., et al. (2008) Substantial Increase in the Use of Adjuvant Systemic Treatment for Early Stage Breast Cancer Reflects Changes in Guidelines in the Period 1990-2006 in the Southeastern Netherlands. European Journal of Cancer, 44, 1846-1854.
http://dx.doi.org/10.1016/j.ejca.2008.06.001

[29]   Mook, S., Schmidt, M., Rutgers, E., van de Velde, A., Visser, O., Rutgers, S., et al. (2009) Calibration and Discriminatory Accuracy of Prognosis Calculation for Breast Cancer with the Online Adjuvant! Program: A Hospital-Based Retrospective Cohort Study. The Lancet Oncology, 10, 1070-1076.
http://dx.doi.org/10.1016/S1470-2045(09)70254-2

[30]   Bontenbal, M., van Putten, W., Burghouts, J., Baggen, M., Ras, G., Stiegelis, W., et al. (2000) Value of Estrogenic Recruitment before Chemotherapy: First Randomized Trial in Primary Breast Cancer. Journal of Clinical Oncology, 18, 734.

[31]   Council of the Dutch Federation of Medical Scientific Societies Code of Conduct for Medical Research.
http://www.federa.org/sites/default/files/bijlagen/coreon/code_of_conduct_for_medical_research_1.pdf

[32]   van den Broek, A., Schmidt, M., van’t Veer, L., Tollenaar, R. and van Leeuwen, F (2015) Worse Breast Cancer Prognosis BRCA1/BRCA2 Mutation Carriers: What’s the Evidence? A Systematic Review with Meta-Analysis. PLoS ONE, 10, e0120189.
http://dx.doi.org/10.1371/journal.pone.0120189

[33]   Siesling, S., van de Poll-Franse, L.V., Jobsen, J.J., Repelaer van Driel, O.J. and Voogd, A.C. (2005) Trends and Variation in Breast Conserving Surgery in the Southeast and East of the Netherlands over the Period 1990-2002. Nederlands Tijdschrift voor Geneeskunde, 149, 1941-1946.

[34]   Bayraktar, S. and Glück, S. (2012) Systemic Therapy Options in BRCA Mutation-Associated Breast Cancer. Breast Cancer Research and Treatment, 135, 355-366.
http://dx.doi.org/10.1007/s10549-012-2158-6

[35]   Kriege, M., Seynaeve, C., Meijers-Heijboer, H., Collee, J., Menke-Pluymers, M., Bartels, C., et al. (2009) Sensitivity to First-Line Chemotherapy for Metastatic Breast Cancer in BRCA1 and BRCA2 Mutation Carriers. Journal of Clinical Oncology, 27, 3764-3771.

[36]   van Steenbergen, L., Poll-Franse, L., Wouters, M., Jansen-Landheer, M., Coebergh, J., Struikmans, H., et al. (2010) Variation in Management of Early Breast Cancer in the Netherlands, 2003-2006. European Journal of Surgical Oncology, 36, S36-S43.
http://dx.doi.org/10.1016/j.ejso.2010.06.021

[37]   Degner, L., Kristjanson, L., Bowman, D., Sloan, J., Carriere, K., O’Neil, J., et al. (1997) Information Needs and Decisional Preferences in Women with Breast Cancer. Journal of the American Medical Association, 277, 1485-1492.
http://dx.doi.org/10.1001/jama.1997.03540420081039

[38]   Step, M., Siminoff, L. and Rose, J. (2009) Differences in Oncologist Communication across Age Groups and Contributions to Adjuvant Decision Outcomes. Journal of the American Geriatrics Society, 57, S279-S282.
http://dx.doi.org/10.1111/j.1532-5415.2009.02512.x

[39]   Charles, C., Gafni, A. and Whelan, T. (2004) Self-Reported Use of Shared Decision-Making among Breast Cancer Specialists and Perceived Barriers and Facilitators to Implementing This Approach. Health Expectations, 7, 338-348.
http://dx.doi.org/10.1111/j.1369-7625.2004.00299.x

 
 
Top